PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia
Yizhen Li(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Satoshi Yoshimura(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), Elisabeth Paietta(Montefiore Medical Center), Mark R. Litzow(Mayo Clinic in Arizona), Raul C. Ribeiro(St. Jude Children's Research Hospital), Xujie Zhao(St. Jude Children's Research Hospital), Zhenhua Li(St. Jude Children's Research Hospital), Yang Xu(Guangzhou Center for Disease Control and Prevention), Jiyang Yu(Columbia University Irving Medical Center), Takaya Moriyama(Mie University)
Cited by 34
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914